Breast Cancer – Benefits of Trodelvy in HR+/HER2-
Background The antibody-drug conjugate Trodelvy offers statistically and clinically significant benefits for patients with heavily pretreated HR+/HER2- breast cancer, according to results of the TROPiCS-02
Colorectal Cancer – New 1st for Left-Sided RAS-WT
Overview Colorectal cancer is one of the most common types of malignant tumors in humans. According to statistics, the risk of developing this tumor in
Cholangiocarcinoma – Imfinzi plus Gemzar and Cisplatin
Background Biliary tract cancer is a group of malignancies that includes intrahepatic and extrahepatic cholangiocarcinoma, gallbladder cancer, and ampulla of Vater cancer. It is typically
Endometrial Cancer – Vistusertib Plus Arimidex in Patients With HR+
Importance Endometrial cancer is often hormone-dependent and treated with aromatase inhibitors, (AIs). The uncontrolled PI3K-AKT-mTOR pathway observed in this type of cancer drives hormonal resistance.
Lung Cancer – Another new drug for EGFR: Ameile
Background Epidermal Growth Factor Receptor, EGFR, mutations are one of the most common driver mutations in Non–Small-Cell Lung Cancer, NSCLC. Tagrisso, a third-generation EGFR tyrosine
Breast Cancer – Topical Ointment for Cutaneous Metastases
Purpose This Phase 1/2 study evaluated safety and efficacy of a topical anhydrous ointment, SOR007, which contains submicron particles of the chemotherapy Taxol primarily in
Cervical Cancer – Positive Results with VB10.16
Overview Cervical cancer is a malignant tumor that grows in different parts of the cervix. The vast majority of cervical cancers are linked to an
Esophageal Cancer – Tislelizumab Beats Chemotherapy
Background Patients with advanced or metastatic esophageal cancer of squamous cell type have poor prognosis. For these patients, treatment options are limited after first therapy.
Prostate Cancer – New Triplet Combination
Background Castration-sensitive prostate cancer, CSPC, is cancer that is controlled by keeping the testosterone level as low as would be expected if the testicles were
Triple Negative Breast Cancer – New Triplet
Background Metastatic Triple Negative Breast Cancer, mTNBC, has limited treatment options for patients and thus represents a highly unmet need. In this phase Ⅱ trial,
Ovarian Cancer – Mirvetuximab Soravtansine Yields Benefit
Background Patients with platinum-resistant ovarian cancer have limited therapeutic options available to them. Treatment is largely comprised of chemotherapy, which is known to have limited
Lung cancer – Toripalimab Plus Chemo is Better than Chemo Alone
Background According to data from the CHOICE-1 trial, Toripalimab (anti–PD-1) in combination with chemotherapy showed significant improvement in the length of time until progression of
